Status:

RECRUITING

Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder

Lead Sponsor:

Vanderbilt University Medical Center

Conditions:

Tourette Syndrome

Tic Disorder

Eligibility:

All Genders

11-17 years

Brief Summary

Individuals with tic disorders have lower quality of life, sensory and movement difficulties, and poorer mental, social, and physical health compared to the general population. Current clinical care f...

Detailed Description

The study consists of 4 visits over the course of 2 years. The first 2 visits will occur within 30 days of each other, and then, two years later, participants will be asked to attend two more study vi...

Eligibility Criteria

Inclusion

  • Inclusion criteria for adolescents with tic disorder:
  • adolescent age 11-17 years of age
  • adolescent diagnosis of chronic tic disorder (Tourette syndrome, chronic motor tic disorder, chronic vocal tic disorder)
  • English-speaking adolescent and caregiver/adult proxy (as validated questionnaires are in English)
  • adolescent and caregiver/adult proxy willingness and ability to complete relevant questionnaires
  • Exclusion criteria for for adolescents with tic disorder:
  • cognitive or attentional impairment precluding ability of adolescent or caregiver/adult proxy to complete questionnaires and other study measures
  • adolescent diagnosis of autism spectrum disorder (ASD) or psychotic disorder
  • adolescent diagnosis of pervasive genetic disorder besides chronic tic disorders and their known comorbidities
  • adolescent with severe medical conditions unrelated to chronic tic disorders (e.g. uncontrolled seizures, prominent heart conditions)
  • other variables that might influence ratings outside of the typical presentation of chronic tic disorders
  • Additional exclusion criteria for EEG tasks for chronic tic disorder sample\*\*
  • adolescent treatment with stimulant medications or anti-seizure medications within the past 30 days
  • use of marijuana or recreational substances within the past 30 days
  • history of seizure
  • history of hearing loss or abnormalities
  • history of neuropathy or overt sensory deficit
  • history of brain surgery or skull-penetrating/deforming trauma
  • history of stroke, brain cancer, or other significant neurologic illness/disorder \*\* Individuals excluded based on these criteria are ineligible for the EEG portion of the study but can complete the remainder of the study measures.
  • Inclusion criteria for control (neurotypical adolescent) participants
  • adolescent age 11-17 years of age
  • English-speaking adolescent and caregiver/adult proxy (as validated questionnaires are in English)
  • adolescent and caregiver/adult proxy willingness and ability to complete relevant questionnaires
  • Exclusion criteria for control sample
  • history of tics, ADHD, OCD, or other significant neurodevelopmental or neuropsychiatric disorder.
  • \*\* Note: adolescents with history of mood or anxiety disorder are eligible.
  • cognitive or attentional impairment precluding ability of adolescent or caregiver/adult proxy to complete questionnaires and other study measures
  • adolescent diagnosis of autism spectrum disorder (ASD) or psychotic disorder
  • adolescent diagnosis of pervasive genetic disorder
  • adolescent with severe medical conditions (e.g. uncontrolled seizures, prominent heart conditions)
  • other variables that might influence ratings
  • Additional exclusion criteria for EEG tasks for control sample\*
  • adolescent treatment with stimulant medications or anti-seizure medications within the past 30 days
  • use of marijuana or recreational substances within the past 30 days
  • history of seizure
  • history of hearing loss or abnormalities
  • history of neuropathy or overt sensory deficit
  • history of brain surgery or skull-penetrating/deforming trauma
  • history of stroke, brain cancer, or other significant neurologic illness/disorder

Exclusion

    Key Trial Info

    Start Date :

    October 24 2024

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    May 1 2030

    Estimated Enrollment :

    351 Patients enrolled

    Trial Details

    Trial ID

    NCT06576726

    Start Date

    October 24 2024

    End Date

    May 1 2030

    Last Update

    November 24 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Vanderbilt University Medical Center

    Nashvile, Tennessee, United States, 37232